Quintiles

Kareus initiates phase I trial in Alzheimer's disease

Friday, January 4, 2013 02:51 PM

Kareus Therapeutics, a private biotechnology company focused on unmet treatment of age-related and chronic diseases, has initiated a phase I clinical study following the Investigational New Drug (IND) approval from the FDA for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.

More... »

INC Research strengthens leadership for strategic advisory services unit

Monday, December 10, 2012 01:44 PM

INC Research, a therapeutically focused CRO, has appointed Robert Ryan, PhD, as vice president of regulatory strategy, consulting and submissions. Ryan will provide global leadership to position INC Strategic Advisory Services as a market leader in regulatory consulting and submissions offerings.

More... »

Drug discovery services market to reach $16.6B in 2015

Monday, December 10, 2012 10:09 AM

A new report by visiongain, an independent media company based in London, predicts that the world market for drug discovery outsourcing will reach $16.6 billion in 2015. That revenue forecast and others appear in “DrugDiscovery Outsourcing: World Market 2013-2023,” published in November 2012.

More... »

CRA enters strategic alliance with Quintiles

Tuesday, November 27, 2012 11:42 AM

Tempe, Ariz.-based Clinical Research Advantage (CRA), a community-based network of clinical trial sites, has entered into a strategic agreement  with CRO Quintiles to facilitate a higher level of clinical trial participation with an emphasis on safety, improved study efficiencies and quality data.

More... »

Quintiles, Scottish health boards partner to accelerate research

Monday, October 1, 2012 09:41 AM

Quintiles, a fully integrated biopharmaceutical services company, formed a strategic partnership with the four teaching health boards—Aberdeen, Dundee, Edinburgh and Glasgow—in Scotland as part of its Prime Site program to accelerate the development of new and more effective medicines.

More... »

ICON adds two to leadership teams in Asia Pacific and Latin America

Friday, September 28, 2012 02:47 PM

ICON,a global provider of outsourced development services, has appointed new members to its Asia Pacific & Latin American teams. New members include Wei Ming Goh as vice president of Asia Pacific and Dennis Hurley as vice president of Latin America.

More... »

Quintiles designates Comprehensive with Prime Site status

Wednesday, September 26, 2012 09:58 AM

CRO Quintiles has designated Comprehensive Clinical Development, a Miramar, Fla.-based clinical research company, as a Quintiles Prime Site—a distinction that gives Comprehensive an enhanced role in global clinical research and testing of new and more effective medicines.

More... »

Quintiles, Sinclair ink 10-year partnership to commercialize portfolio in Mexico

Wednesday, September 19, 2012 11:37 AM

Quintiles, a fully integrated biopharmaceutical services company, and Sinclair IS Pharma, a topicals and supportive care specialist, have signed a 10-year collaboration and licensing agreement for Quintiles (Rowfarma Mexico) to commercialize Sinclair’s portfolio of dermo-cosmetic products and medical devices in Mexico.

More... »

Quintiles acquires Expression Analysis to advance personalized medicine

Monday, August 13, 2012 12:02 PM

Quintiles, a fully integrated biopharmaceutical services company, has acquired Expression Analysis (EA), a Durham, N.C.-based provider of genomics testing and analysis to biopharma, academic, government and non-profit customers. Terms of the transaction were not disclosed.

More... »

German CRO Verum.de opens U.S. office

Wednesday, August 8, 2012 09:24 AM

Verum.de, a German-based CRO, has opened a new office in Carlsbad, Calif.

More... »